AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. NVDA
2. ORCL
3. USO
4. SPY
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. ENB
10. SATL

Go back to AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
(NASDAQ: ABCL) Delayed: 11.17 +0.28 (2.57%)
Previous Close $10.89    52 Week High $ 
Open $10.66    52 Week Low $ 
Day High $11.31    P/E N/A 
Day Low $10.66    EPS $ 
Volume 4,444,990